EICHORCondition: Kidney Disease, Chronic · Transplant Recipient (Kidney) · Immunosuppression · Sponsor: Instituto de Investigación Hospital Universitario La Paz
This is a phase IV multicentre adaptive single-blinded randomized clinical trial to evaluate if preemptively genotyping populations at pretransplant chronic kidney disease susceptible of receiving tacrolimus therapy is effective, cost-effective, and feasible within the Spanish National Health System when compared to the current standard of care. This trial is nested within the iPHARMGx master protocol.
This description comes directly from the study's public registry record.
Alberto M. Borobia, MD, PhD · +34 912071466 · alberto.borobia@salud.madrid.org
Always discuss trial participation with your own doctor first.
| Hospital La Paz | Madrid, Madrid, Spain | Recruiting |
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06701825